Methotrexate Shows Cardiovascular Benefits Beyond Arthritis Treatment in New Study

Methotrexate查看药品详情, a cornerstone treatment for rheumatoid arthritis (搜索)搜索该疾病, demonstrated significant cardiovascular benefits beyond its anti-inflammatory effects in a new controlled study. The research, published in Annals of Medicine, found that the drug substantially lowered systolic blood pressure compared to another disease-modifying antirheumatic drug (DMARD) in newly diagnosed patients.

Study Design and Key Findings

The six-month controlled comparative study followed 62 treatment-naïve adults with newly diagnosed rheumatoid arthritis (搜索)搜索该疾病. Half received subcutaneous methotrexate查看药品详情 while the other half took oral sulfasalazine查看药品详情. Researchers measured changes in blood pressure, arterial stiffness, and disease activity throughout the study period.

By six months, patients treated with methotrexate查看药品详情 showed a mean reduction in systolic blood pressure of 7.4 mm Hg compared with those taking sulfasalazine查看药品详情 (95% CI, −14.0 to −0.8; P = .03). Lead author Arduino A. Mangoni, MD, PhD, strategic professor and head of clinical pharmacology at Flinders University查看公司主页, described this reduction as clinically meaningful.

"We've known for a while that methotrexate查看药品详情 helps with inflammation, but now we're seeing that it may also help lower blood pressure, which is a major risk factor for heart disease," Mangoni said. "This could be a big step forward in how we care for people with rheumatoid arthritis (搜索)搜索该疾病."

Cardiovascular Risk Context in RA

Rheumatoid arthritis (搜索)搜索该疾病 affects approximately 1 in 100 people worldwide and is associated with systemic inflammation, endothelial dysfunction, and heightened cardiovascular disease (搜索)搜索该疾病 risk. Hypertension (搜索)搜索该疾病 and arterial stiffness are common comorbidities that increase the likelihood of heart attacks and strokes among individuals with RA.

While past observational studies have linked methotrexate查看药品详情 to reductions in cardiovascular-related mortality and morbidity in autoimmune disease populations, those studies did not establish causality. The current findings provide prospective comparative evidence that methotrexate lowers systolic blood pressure in patients with RA, independent of improvements in joint disease activity or arterial stiffness.

Mechanisms Beyond Joint Inflammation

The blood pressure reduction appeared unrelated to changes in arthritis symptoms or arterial stiffness, suggesting methotrexate查看药品详情 may help cardiovascular health through alternative mechanisms such as calming inflammation or improving blood vessel function. According to the researchers, this proposition is further supported by the lack of between-group differences in the use of other drugs affecting blood pressure, including antihypertensive medications, corticosteroids, and nonsteroidal anti-inflammatory drugs.

Genetic Factors Influence Response

The study also examined whether genetic variations influenced blood pressure outcomes. Researchers found that patients with certain single nucleotide polymorphisms (SNPs), including rs1801133 in the MTHFR (搜索)搜索该靶点 gene and rs2231142 in the ABCG2 (搜索)搜索该靶点 gene, experienced greater reductions in blood pressure while on methotrexate查看药品详情.

"The specific associations between rs1801133 (MTHFR (搜索)搜索该靶点) and rs2231142 (ABCG2 (搜索)搜索该靶点) and blood pressure changes during methotrexate查看药品详情 treatment are supported by the concomitant lack of associations between these SNPs and blood pressure changes with sulfasalazine查看药品详情," the authors noted.

These findings suggest a potential role for pharmacogenetics in tailoring RA treatment, opening the door to more personalized treatment options where doctors could use genetic testing to predict who might benefit most from methotrexate查看药品详情's heart-protective effects.

Study Limitations and Future Directions

The researchers acknowledged several limitations, including that treatment allocation was not randomized but based on clinical judgment, raising the potential for confounding by indication. Additionally, the sample size was relatively small, and patient attrition was higher in the sulfasalazine查看药品详情 group.

Study coordinator Sara Tommasi, PhD, medical scientist at Southern Adelaide Local Health Network (搜索)搜索该词条, emphasized that while more research is needed to confirm these findings and understand exactly how methotrexate查看药品详情 lowers blood pressure, the results are promising. "The results suggest that this well-known arthritis drug could also play a role in protecting heart health, especially in people who are at higher risk due to inflammation," she said.